Claire Smith

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla et al. · British Journal of Cancer · 2018 · 274 citations · Full text

Medicine, Oncology, Pharmacology +13

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2016 · 271 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Christophe Massard, A. Ázaro, Jean‐Charles Soria et al. · Annals of Oncology · 2018 · 163 citations · Full text

Medicine, Oncology, Pharmacology +14

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Sandrine Faivre, Armando Santoro, Robin Kate Kelley et al. · Liver International · 2019 · 143 citations

Medicine, Oncology, Pharmacology +17

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla et al. · Cancer Chemotherapy and Pharmacology · 2019 · 92 citations

Medicine, Cancer Biology, Oncology +15